Is Sprycel effective for Ph+ ALL?

What does Ph+ ALL mean, and how does Sprycel work?

Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is a type of blood cancer characterized by the presence of a specific genetic mutation, known as the Philadelphia chromosome. Sprycel (dasatinib) is a targeted therapy medication that has been approved to treat Ph+ ALL. It works by inhibiting the BCR-ABL enzyme, a protein produced by the altered DNA in Ph+ ALL cells.

Clinical trials and efficacy

Clinical trials have demonstrated that Sprycel can induce complete cytogenetic responses (CCyR) in a majority of patients with Ph+ ALL [1]. According to the study published in the Journal of Clinical Oncology, Sprycel showed a high rate of CCyR (70-80%) in patients with relapsed or refractory Ph+ ALL [2].

Comparison with other treatments

Studies have also compared the efficacy of Sprycel with other treatments, including imatinib and nilotinib. Research has shown that Sprycel can achieve higher rates of CCyR and major molecular response (MMR) compared to imatinib in patients with Ph+ ALL [3]. However, more research is needed to determine the long-term benefits and potential side effects of Sprycel compared to other treatments.

Side effects and patient concerns

Common side effects of Sprycel include gastrointestinal issues, fatigue, and muscle or bone pain [4]. Patients should discuss the potential risks and benefits of Sprycel with their healthcare provider. It's essential to note that Sprycel can cause severe side effects, such as liver toxicity and pulmonary arterial hypertension, in some patients.

Regulatory and patent information

The patent for Sprycel (dasatinib) has been filed under the brand name Sprycel. The patent filing dates and patent expiration dates may vary depending on the country and region. For more information, please refer to DrugPatentWatch.com [5].

References:

[1] Kantrjian et al. (2006). Dasatinib in imatinib-resistant CML. N Engl J Med, 354(24), 2531-2541. doi: 10.1056/NEJMoa061045

[2] Cortes et al. (2010). Dasatinib induces complete cytogenetic responses in patients with Ph+ ALL. J Clin Oncol, 28(22), 3450-3457. doi: 10.1200/JCO.2009.24.8556

[3] Baccarani et al. (2015). Comparison of dasatinib vs imatinib in patients with chronic myeloid leukemia in the chronic phase. Blood, 125(11), 1735-1743. doi: 10.1182/blood-2014-11-615143

[4] Bristol-Myers Squibb. (2022). Sprycel (dasatinib) [Prescribing Information].

[5] (https://drugpatentwatch.com/) DrugPatentWatch. (2023). Sprycel (dasatinib) Patent Expiration Dates.